Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

AccesswireDec 19, 2024 16:05 ET

Clear Street Launches Healthcare & Biotechnology Equity Research

BusinesswireDec 17, 2024 14:00 ET

BTIG Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Maintains Target Price $67

Moomoo NewsDec 10, 2024 13:32 ET · Ratings

JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58

Moomoo NewsDec 10, 2024 12:32 ET · Ratings

Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership

TipRanksDec 10, 2024 12:05 ET · Ratings

H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50

Moomoo NewsDec 10, 2024 07:31 ET · Ratings